Premium
Oxygen‐Boosted Chemotherapy: Oxygen Nanocarrier for Combined Cancer Therapy: Oxygen‐Boosted ATP‐Responsive Chemotherapy with Amplified ROS Lethality (Adv. Healthcare Mater. 17/2016)
Author(s) -
Zhao Pengfei,
Zheng Mingbin,
Luo Zhenyu,
Fan Xiujun,
Sheng Zonghai,
Gong Ping,
Chen Ze,
Zhang Baozhen,
Ni Dapeng,
Ma Yifan,
Cai Lintao
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201670090
Subject(s) - nanocarriers , oxygen , reactive oxygen species , chemotherapy , cancer cell , cancer research , medicine , cancer , chemistry , pharmacology , biochemistry , drug , organic chemistry
An oxygen nanocarrier (A/D‐ONC) absorbing doxorubicin‐intercalated DNA duplex is developed by Jin Chang, Nan Ma, Rainer Haag and co‐workers on page 2161. After cell endocytosis, oxygenated A/D‐ONC donates O 2 to cancer cells for therapy by two ways: 1) increase intracellular ATP content to promote ATP‐responsive DOX release for chemotherapy, converting ATP to the activator of detrimental chemotherapy; 2) synchronously increase reactive oxygen species (ROS) amount to amplify the lethality to cancer cells.